Evidence map›Paper›PMID 34657251›Full record

ReviewMolecular biology reports2022

The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword.

Mohammad Heydarian, Mohammadjavad Mohammadtaghizadeh, Mahboobeh Shojaei, Marziyeh Babazadeh, Sadegh Abbasian, Mehran Amrovani

Open access · bronzeAbstract readReview
In one paragraph

Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Mohammad HeydarianLorestan University of Medical Sciences, Khorramabad, Iran.
Mohammadjavad MohammadtaghizadehAtherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mahboobeh ShojaeiHigh Institute for Education and Research in Transfusion Medicine, Tehran, Iran.
Marziyeh BabazadehDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Sadegh AbbasianDepartment of Laboratory Science, School of Paramedical Sciences, Ilam University of Medical Sciences, Ilam, Iran.
Mehran AmrovaniHigh Institute for Education and Research in Transfusion Medicine, Tehran, Iran. e.amrovani@gmail.com.ORCID http://orcid.org/0000-0001-8742-3628
High Institute for Education and Research in Transfusion Medicine · IRAhvaz Jundishapur University of Medical Sciences · IRLorestan University of Medical Sciences · IRMedical University of Ilam · IRShiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSevere acute respiratory syndrome coronavirus 2 (SARS-COV2) was first detected in Wuhan, China in December, 2019. The emerging virus causes a respiratory illness, that can trigger a cytokine storm in the body.

methodCytokine storm in patient's body is associated with severe forms of disease. It is one of the main complications of coronavirus disease-2019 (COVID-19), in which immune cells play a major role. Studies have shown immune cells in the tumor environment can be effective to induce resistance to chemotherapy in cancer patients.

resultTherefore, considering the role of immune cells to induce cytokine storm in COVID-19 patients, and their role to cause resistance to chemotherapy, they are effective on disease progression and creation of severe form of disease.

conclusionBy examining the signaling pathways and inducing resistance to chemotherapy in tumor cells and the cells affect them, it is possible to prevent the occurrence of severe forms of the disease in cancer patients with COVID-19; it is applicable using target therapy and other subsequent treatment strategies.

Indexed as

COVID-19Cytokine Release SyndromeAntineoplastic AgentsDrug ResistanceHumansNeoplasmsSARS-CoV-2Antineoplastic AgentsChemotherapy resistanceCOVID-19Cytokine stormPathogenesis

Identifiers

PMID34657251
PMCPMC8520341
OpenAlexW3207301049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.